Total Funding
72
Total FundingSeries A raised
Growth Score
pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications.
- Gary Flynn: Founder
About the Company
Vibliome has discovered a new systematic approach that enables the development of small molecule kinase inhibitors with unique selectivity profiles and, in some cases, extraordinary selectivity. There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatory
serine, threonine, or tyrosine residues on proteins. The versatility of our chemistry platform offers many opportunities for variation while maintaining a common general architecture.
